Research on longevity in humans has shown that reducing inflammation can extend human lifespan and improve overall health outcomes
The numbers should never be used interchangeably without prescriber guidance
Research Insights Weight Loss and Obesity Management Clinical studies show that individuals treated with GLP-1 (S) experienced weight reductions of up to 15% over 68 weeks, significantly outperforming placebo groups ( 2, 3 )
A threshold analysis found that a 71.6% WAC discount would be required for oral semaglutide 14 mg to generate 5-year per-patient costs equal to those of the sitagliptin 100 mg pathway (scenario 6)
This "Ozempic effect" has led to a surge in skin-tightening and body-sculpting procedures, but a crucial part of a successful GLP-1 weight loss journey is building muscle back
Peptide quality, dosing, route of administration, and patient selection matter enormouslyand the U.S